Literature DB >> 12637583

Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems.

Louise Royle1, Anja Roos, David J Harvey, Mark R Wormald, Daniëlle van Gijlswijk-Janssen, El-Rashdy M Redwan, Ian A Wilson, Mohamed R Daha, Raymond A Dwek, Pauline M Rudd.   

Abstract

Secretory IgA (SIgA) is a multi-polypeptide complex consisting of a secretory component (SC) covalently attached to dimeric IgA containing one joining (J) chain. We present the analysis of both the N- and O-glycans on the individual peptides from this complex. Based on these data, we have constructed a molecular model of SIgA1 with all its glycans, in which the Fab arms form a T shape and the SC is wrapped around the heavy chains. The O-glycan regions on the heavy (H) chains and the SC N-glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids. These glycan epitopes provide SIgA with further bacteria-binding sites in addition to the four Fab-binding sites, thus enabling SIgA to participate in both innate and adaptive immunity. We also show that the N-glycans on the H chains of both SIgA1 and SIgA2 present terminal GlcNAc and mannose residues that are normally masked by SC, but that can be unmasked and recognized by mannose-binding lectin, by disrupting the SC-H chain noncovalent interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637583     DOI: 10.1074/jbc.M301436200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  117 in total

Review 1.  Secretory IgA: arresting microbial pathogens at epithelial borders.

Authors:  Nicholas J Mantis; Stephen J Forbes
Journal:  Immunol Invest       Date:  2010       Impact factor: 3.657

Review 2.  The role of secretory antibodies in infection immunity.

Authors:  Richard A Strugnell; Odilia L C Wijburg
Journal:  Nat Rev Microbiol       Date:  2010-08-09       Impact factor: 60.633

3.  Development of immunoglobulin A nephropathy- like disease in beta-1,4-galactosyltransferase-I-deficient mice.

Authors:  Toshikazu Nishie; Osamu Miyaishi; Haruhito Azuma; Akihiko Kameyama; Chie Naruse; Noriyoshi Hashimoto; Hitoshi Yokoyama; Hisashi Narimatsu; Takashi Wada; Masahide Asano
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

4.  Binding of the streptococcal surface glycoproteins GspB and Hsa to human salivary proteins.

Authors:  Daisuke Takamatsu; Barbara A Bensing; Akraporn Prakobphol; Susan J Fisher; Paul M Sullam
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

Review 5.  Immunoglobulin A: A next generation of therapeutic antibodies?

Authors:  Jantine E Bakema; Marjolein van Egmond
Journal:  MAbs       Date:  2011-07-01       Impact factor: 5.857

Review 6.  Glycan recognition at the saliva - oral microbiome interface.

Authors:  Benjamin W Cross; Stefan Ruhl
Journal:  Cell Immunol       Date:  2018-08-18       Impact factor: 4.868

7.  Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.

Authors:  Lei Zhu; Qingcheng Guo; Huaizu Guo; Tao Liu; Yingxin Zheng; Peiming Gu; Xi Chen; Hao Wang; Sheng Hou; Yajun Guo
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 8.  On-line separations combined with MS for analysis of glycosaminoglycans.

Authors:  Joseph Zaia
Journal:  Mass Spectrom Rev       Date:  2009 Mar-Apr       Impact factor: 10.946

Review 9.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2003-2004.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2009 Mar-Apr       Impact factor: 10.946

10.  Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding.

Authors:  Michelle M Gomes; Stephanie B Wall; Kazuo Takahashi; Jan Novak; Matthew B Renfrow; Andrew B Herr
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.